TICKERNERD
Menu
BBNXBBNXHealthcare · Medical Devices

BBNX Stock Forecast: Beta Bionics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$13
+4.05% on the day

The 11 Wall Street analysts covering Beta Bionics, Inc. hold a median 12-month price target of $20 — +49.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$600.6M
Ticker Nerd rank
37 / 100
Median analyst target
$20
Analysts covering
11
Total return, dividends reinvested
1W
−16.5%
1M
−20.3%
YTD
−56.2%
1Y
−18.6%
From 52W high
−58.3%
From 52W low
+50.7%
$9
$32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BBNX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Beta Bionics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
64
Growth
63
Accruals
56
Size
51
Volatility
45
Value
44
Issuance
36
Quality
32
Momentum
24

Revisions (64): Analysts have, on balance, been raising their forecasts.

Momentum (24): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Beta Bionics, Inc. — and when they’d sell — is the membership.

Wall Street

BBNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BBNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26BBNXHigh $30Median $20Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
8 Buy3 Hold0 Sell
Low $14Median $20High $30

The green dot is the last close — the median target sits +49.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 July 2026UBSAssumesBuy$22
15 July 2026Goldman SachsMaintainsBuy—
15 July 2026Goldman SachsMaintainsBuy$17 → $19
13 July 2026Truist SecuritiesMaintainsBuy—
13 July 2026Truist SecuritiesMaintainsBuy$18 → $22
27 May 2026Goldman SachsMaintainsBuy—
18 May 2026B of A SecuritiesMaintainsNeutral—
22 Apr 2026Leerink PartnersMaintainsOutperform—
22 Apr 2026StifelMaintainsBuy—
15 Apr 2026Truist SecuritiesMaintainsBuy—
9 Apr 2026Goldman SachsMaintainsBuy—
18 Feb 2026BairdMaintainsNeutral—
18 Feb 2026StifelMaintainsBuy—
4 Feb 2026StifelMaintainsBuy—
2 Feb 2026Truist SecuritiesMaintainsBuy—
27 Jan 2026TD CowenInitiatesHold—
9 Jan 2026Lake StreetMaintainsBuy—
5 Jan 2026B of A SecuritiesMaintainsBuy—
18 Dec 2025Truist SecuritiesMaintainsBuy—
29 Oct 2025Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

BBNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Beta Bionics, Inc. (BBNX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.4×

Cheaper than 91% of US stocks

Price / sales
5.0×

Cheaper than 24% of US stocks

Price / book
2.3×

Cheaper than 41% of US stocks

EV / EBITDA
−5.0×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
37.8%

Higher than 83% of US stocks

Earnings growth (YoY)
37.8%

Higher than 73% of US stocks

Gross margin
59.0%

Higher than 74% of US stocks

Operating margin
−79.9%

Higher than 15% of US stocks

Net margin
−61.3%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−26.2%

Higher than 29% of US stocks

Return on assets
−16.7%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BBNX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BBNXBeta Bionics, Inc.$600.6M
37
CTKBCytek Biosciences, Inc.$545.0M
60
KIDSOrthoPediatrics Corp.$506.3M
60
TCMDTactile Systems Technology, Inc.$635.4M
100
CBLLCeribell, Inc.$656.2M
28
SIShoulder Innovations, Inc.$471.6M
24
VREXVarex Imaging Corp.$469.1M
82
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BBNX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest BBNX news & analysis

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

GlobeNewsWire · 30 July 2026negative

Johnson Fistel, PLLP is investigating potential securities law violations by Beta Bionics, alleging that the company or its executives may have made false or misleading statements or failed to disclose material information regarding growth trends, new patient starts, business outlook, and related operating metrics.

Why it matters — Shareholders should be aware of the investigation as it raises questions about the accuracy of Beta Bionics' public disclosures and could lead to legal liabilities or penalties.

Beta Bionics, Inc. (BBNX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 30 July 2026neutral

Beta Bionics, Inc. held its Q2 2026 earnings call and the transcript was published by Seeking Alpha.

Why it matters — Earnings call transcripts provide direct insight into management's discussion of quarterly performance and outlook.

Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 29 July 2026positive

Beta Bionics reported a Q2 loss of $0.53 per share, narrower than the Zacks Consensus Estimate of a $0.62 loss but wider than the $0.39 per share loss from the same quarter last year.

Why it matters — The company's quarterly loss came in smaller than analysts had anticipated, indicating performance that exceeded expectations on the bottom line.

Beta Bionics Q2 Earnings Call Highlights

MarketBeat · 29 July 2026positive

Beta Bionics reported second-quarter 2026 net sales of $32 million, up roughly 38% year over year. Growth was driven by new patient starts and recurring pharmacy-channel supply revenue for its iLet insulin-delivery system.

Why it matters — The quarterly results provide investors with a read on commercial adoption and revenue momentum for the company's lead product, the iLet system.

FAQ

Frequently asked questions about BBNX stock

What is the BBNX stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Beta Bionics, Inc. have a median 12-month price target of $20, with estimates ranging from $14 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BBNX stock a buy right now?

Of the 11 analysts covering Beta Bionics, Inc., 8 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beta Bionics, Inc. 37 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BBNX?

As at 1 Aug 2026, Beta Bionics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (64 of 100).

Will BBNX stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +49.8% from the last close, and Ticker Nerd's factor model ranks Beta Bionics, Inc. 37 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BBNX stock forecast for 2030?

No analyst covering Beta Bionics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $30 over the next 12 months.

How has BBNX stock performed over the past year?

Beta Bionics, Inc. returned -18.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Beta Bionics, Inc. do?

Beta Bionics Inc. is a commercial-stage medical device company focused on designing, developing, and commercializing advanced solutions to improve the health and quality of life for people requiring insulin due to diabetes.

What is the latest news on BBNX?

The most recent item we track (GlobeNewsWire, 30 July 2026): "Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders". Johnson Fistel, PLLP is investigating potential securities law violations by Beta Bionics, alleging that the company or its executives may have made false or misleading statements or failed to disclose material information regarding growth trends, new patient starts, business outlook, and related operating metrics.

Company

About Beta Bionics, Inc.

Beta Bionics Inc. is a commercial-stage medical device company focused on designing, developing, and commercializing advanced solutions to improve the health and quality of life for people requiring insulin due to diabetes. Its flagship product, the iLet Bionic Pancreas, is an FDA-cleared automated insulin delivery system for treating type 1 diabetes in adults and children aged six and older. This innovative device autonomously calculates and delivers 100% of insulin doses using data from compatible continuous glucose monitors like Dexcom or FreeStyle Libre 3 Plus, eliminating the need for carb counting or manual corrections. The company offers the recently introduced Color iLet with an enhanced color screen, brighter display, and louder alerts. Beta Bionics Inc. is also advancing a Patch Pump that adheres directly to the skin without tubing, a Bihormonal iLet combining insulin and glucagon delivery, and an iLet for insulin-dependent type 2 diabetes. It maintains collaborations with Xeris Pharmaceuticals for pump-compatible glucagon and Abbott Diabetes Care for automated insulin delivery systems. Founded in 2015 and headquartered in Irvine, California, Beta Bionics Inc. serves the diabetes community through durable medical equipment and pharmacy benefit plan channels, including a Pharmacy Advantage Program offering the first 30 days free.

CEO Mr. Sean T. Saint PE · 420 employees · United States · https://www.betabionics.com